Gedatolisib (Ged) vs Other Regimens Post-CDK4/6i and Endocrine Therapy (ET) in PIK3CA Wild-Type (WT) HR+/ HER2- Advanced Breast Cancer (aBC): A Network Meta-Analysis (NMA)

Revtorpyk (gedatolisib) - Celcuity

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/print/presentation/6826

Sara M. Tolaney; Vijayakrishna K. Gadi; Rena Callahan; Barbara Pistilli; Evan Popoff; Michael J. Zoratti; Alana Stilla; Thelma Ubani; Anik Patel; Sidonie N. Niba; Chiemeka Ike; Seth A. Wander

Jul 17, 2026